查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1948191

全球體學CRO服務市場：機會與策略展望（至2034年）

Omics CRO Services Global Market Opportunities And Strategies To 2034
出版日期: | 出版商: The Business Research Company | 英文 420 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

全球體學CRO服務市場預計到2024年將達到約342.0994億美元，自2019年以來年複合成長率（CAGR）為13.55%。該市場預計將從2024年的342.0994億美元成長到2029年的616.2889億美元，年複合成長率為12.49%。此後，預計從2029年起將繼續以10.77%的年複合成長率成長，到2034年達到1027.9404億美元。

體學CRO（受託研究機構）服務是指外包研究解決方案，專門從事基因組學、轉錄組學、蛋白質組學、代謝體學和表觀基因等領域的大規模生物數據分析。這些服務提供全面的支持，包括樣本處理、高通量數據生成、生物資訊分析和解讀，從而加速製藥、生物技術和個人化醫療領域的研發。體學CRO服務的主要目標是使機構能夠有效率地進行複雜的、高通量的體學研究，而無需對其自身基礎設施進行大量投資。

體學CRO 服務市場由外包研究和分析服務組成，這些服務應用各種技術進行藥物發現、精準醫療和生物標記識別，由組織、自僱人士或夥伴關係等營業單位提供。

有利的政府政策

過去，有利的政府政策推動了體學CRO服務市場的成長。這些政策，例如增加精準醫療的資金投入、津貼基因組研究以及構建支持性的法規結構，透過促進先進定序、生物標記發現和多組體學能力的拓展，體學CRO服務提供了支持。這些政策降低了CRO的財務和營運門檻，促進了創新和先進技術的應用。此外，政府支持的臨床試驗和數據共用計畫加速了研究合作和全球服務部署。例如，2023年9月，美國國立衛生研究院（NIH）成立了一個聯盟，初始資金為5,030萬美元，旨在推動多體學研究，重點是整合各種體學資料類型，以研究不同人群的健康和疾病狀況。這項措施為專注於多體學服務的CRO提供了機會。因此，有利的政府政策推動了體學CRO服務市場的成長。

策略聯盟旨在加強技術整合

體學CRO服務市場的主要企業正在建立策略夥伴關係，以加強技術整合並擴大市場覆蓋範圍。策略夥伴關係通常指的是兩個或多個組織為了實現通用目標而分享資源、專業知識和努力的合作關係。例如，2024年11月，總部位於美國的合約研究組織（CRO）Frontage Laboratories與總部位於波蘭的臨床和診斷服務供應商。此次策略合作旨在將Frontage的臨床試驗服務與Medicover先進的基因組檢測解決方案結合。 Medicover在13個國家經營100多個實驗室，提供全面的基因組分析服務，包括次世代定序（NGS）、分子病理學和藥物基因組學。

全球體學CRO服務市場集中度較高，主要由主要企業主導。到2024年，排名前十的公司將佔據15.12%的市場佔有率。

目錄

第1章執行摘要

第2章 目錄

第3章表格一覽

第4章圖表一覽

第5章 報告結構

第6章 市場特徵

  • 一般市場定義
  • 概述
  • 體學CRO服務市場定義與細分
  • 按體學服務類型分類的市場細分
    • 基因組學
    • 轉錄組學
    • 蛋白質體學
    • 代謝體學
    • 脂質組學
    • 多體學
    • 單細胞體學
    • 其他體學服務
  • 按技術平台分類：市場細分
    • 次世代定序（NGS）
    • 微陣列技術
    • 質譜分析
    • 層析法
    • 生物資訊學工具
    • 其他技術平台
  • 按應用領域分類：市場細分
    • 藥物發現與開發
    • 診斷
    • 個人化醫療
    • 其他用途
  • 按最終用戶分類：市場細分
    • 研究和學術機構
    • 製藥和生物技術公司
    • 臨床和診斷檢測機構

第7章：主要市場趨勢

  • 策略聯盟旨在加強技術整合
  • 策略合作推進先進的空間轉錄組學
  • 下一代基於類器官的篩檢解決方案

第8章 全球體學CRO服務成長分析及策略分析框架

  • 全球體學CRO服務PESTEL分析（政治、社會、技術、環境、法律因素、促進因素與限制因素）
  • 最終用戶分析（B2B）
    • 研究和學術機構
    • 製藥和生物技術公司
    • 臨床和診斷檢查室
  • 全球體學CRO服務市場規模及成長分析
  • 2019-2024年市場成長表現
    • 2019-2024年市場促進因素
    • 2019-2024年市場限制因素
  • 市場成長預測，2024-2029年，2034年預測
  • 預計成長要素/驅動力
    • 定量成長要素
    • 促進要素
    • 抑制因素
  • 最大潛在市場規模：體學CRO服務市場
    • TAM比較分析

9. 全球體學CRO服務市場：細分

  • 全球體學CRO服務市場：依體學服務類型分類，實際數據和預測數據（2019-2024年、2029年預測、2034年預測）。
  • 全球體學CRO服務市場依技術平台分類：實際值及預測值，2019-2024年、2029年預測值、2034年預測值
  • 全球體學CRO服務市場：按應用、效能和預測分類，2019-2024年、2029年預測、2034年預測
  • 全球體學CRO服務市場：依最終用戶分類，實際數據和預測數據，2019-2024年、2029年預測值、2034年預測值
  • 全球體學CRO服務市場：依藥物發現與開發、應用、績效與預測進行細分（2019-2024年、2029年預測、2034年預測）。

第10章：中國市場

第11章 日本市場

第12章 歐洲市場

第13章：美國市場

第14章：加拿大市場

第15章：全球競爭格局及公司概況

  • 公司簡介
  • Labcorp Holding Inc. (including Covance)
  • Thermo Fisher Scientific Inc. (PPD)
  • Charles River Laboratories International Inc.
  • Eurofins Scientific SE
  • BGI Genomics Co. Ltd.

第16章：其他領先和創新企業

  • Novogene Co. Ltd.
  • GENEWIZ from Azenta
  • Frontage Laboratories
  • Somalogic Inc.（SomaScan（R））
  • Metabolon Inc.

第17章：全球十大公司的優勢與劣勢訊息

  • Labcorp Holding Inc. (including Covance)
  • Thermo Fisher Scientific Inc. (PPD)
  • Charles River Laboratories
  • Eurofins Scientific SE
  • BGI Genomics Co. Ltd.
  • Novogene Co. Ltd.
  • GENEWIZ from Azenta
  • Frontage Laboratories
  • Somalogic Inc. (SomaScan(R))
  • Metabolon Inc.

第18章：全球十大公司人工智慧/機器學習能力資訊

  • Labcorp Holding Inc. (including Covance)
  • Thermo Fisher Scientific Inc. (PPD)
  • Charles River Laboratories
  • Eurofins Scientific SE
  • BGI Genomics Co. Ltd.
  • Novogene Co. Ltd.
  • GENEWIZ from Azenta
  • Frontage Laboratories
  • Somalogic Inc. (SomaScan(R))
  • Metabolon Inc.

第19章：全球十大公司創新資訊（包括創新類型的描述）

  • Labcorp Holding Inc. (including Covance)
  • Thermo Fisher Scientific Inc. (PPD)
  • Charles River Laboratories
  • Eurofins Scientific SE
  • BGI Genomics Co. Ltd.
  • Novogene Co. Ltd.
  • GENEWIZ from Azenta
  • Frontage Laboratories
  • Somalogic Inc. (SomaScan(R))
  • Metabolon Inc.

第20章：全球排名前十的公司在其蛋白質組學、代謝體學和脂質組學平台/計劃中具體採用的技術資訊

  • Labcorp Holding Inc. (including Covance)
  • Thermo Fisher Scientific Inc. (PPD)
  • Charles River Laboratories
  • Eurofins Scientific SE
  • BGI Genomics Co. Ltd.
  • Novogene Co. Ltd.
  • GENEWIZ from Azenta
  • Frontage Laboratories
  • Somalogic Inc. (SomaScan(R))
  • Metabolon Inc.

第21章：全球前10大公司的全面能力和技術訊息，包括覆蓋範圍、動態範圍、靈敏度和可重複性

  • Labcorp Holding Inc. (including Covance)
  • Thermo Fisher Scientific Inc. (PPD)
  • Charles River Laboratories
  • Eurofins Scientific SE
  • BGI Genomics Co. Ltd.
  • Novogene Co. Ltd.
  • GENEWIZ from Azenta
  • Frontage Laboratories
  • Somalogic Inc. (SomaScan(R))
  • Metabolon Inc.

第22章體學CRO服務市場的主要企業

第23章：歐洲競爭格局及公司概況

  • 公司簡介
  • Charles River Laboratories International Inc.
  • Labcorp Holdings Inc.
  • Thermo Fisher Scientific Inc.
  • Eurofins Scientific SE.
  • BGI Genomics Co. Ltd.
  • Novogene Co. Ltd.
  • GENEWIZ from Azenta
  • Frontage Laboratories
  • Somalogic Inc.
  • Metabolon Inc.

第24章英國競爭格局及公司概況

  • 公司簡介（簡化版）
  • Eurofins Scientific SE
  • Charles River Laboratories Company
  • Labcorp Holding Inc.
  • Thermo Fisher Scientific Inc.
  • BGI Genomics Co. Ltd.
  • Novogene Co. Ltd.
  • GENEWIZ from Azenta
  • Frontage Laboratories
  • Metabolon Inc.
  • Somalogic Inc.

第25章 德國競爭格局及公司概況

  • 公司簡介/產品與服務
  • Labcorp Holding Inc. (including Covance)
  • Thermo Fisher Scientific Inc. (PPD)
  • Eurofins Scientific SE
  • Charles River Laboratories
  • BGI Genomics Co. Ltd.
  • Novogene Co. Ltd.
  • GENEWIZ from Azenta
  • Somalogic Inc. (SomaScan(R))
  • Centogene GmbH
  • Frontage Laboratories

第26章 美國競爭格局與公司概況

  • 概述
  • Labcorp Holding Inc. (including Covance)
  • Thermo Fisher Scientific Inc. (PPD)
  • Charles River Laboratories
  • Eurofins Scientific SE
  • BGI Genomics Co. Ltd.
  • Novogene Co. Ltd.
  • GENEWIZ from Azenta
  • Frontage Laboratories
  • Somalogic Inc. (SomaScan(R))
  • Metabolon Inc.

第27章：日本的競爭格局與公司概況

  • 公司簡介（簡化版）
  • Eurofins Scientific SE
  • Charles River Laboratories
  • Thermo Fisher Scientific Inc. (PPD)
  • BGI Genomics Co. Ltd.
  • Labcorp Holding Inc. (including Covance)
  • Novogene Co. Ltd.
  • GENEWIZ from Azenta
  • Frontage Laboratories
  • Somalogic Inc. (SomaScan(R))
  • Centogene GmbH

第28章：主要體學CRO服務公司列表（按國家/地區分類）

  • 法國
  • 義大利
  • 西班牙
  • 其他歐洲國家
  • 加拿大
  • 中國
  • 印度

第29章體學CRO服務市場技術平台中人工智慧/機器學習的當前活用狀況

第30章：主要客戶公司列表

第31章 相對需求/服務規模

  • 目標檢驗
  • 風險降低計劃
  • 從熱門歌曲到熱門歌曲
  • 生物標記鑑定
  • 改進製造程序
  • 原料藥分析
  • 毒性評價
  • 數據視覺化
  • 解讀人工智慧/機器學習

第32章：AI/ML在體學CRO計劃決策的應用頻率

  • 基因組學：分析序列資料並識別遺傳模式
  • 轉錄組學：RNA資料解讀與表達定量
  • 蛋白質體學：蛋白質分類與修飾檢測
  • 代謝體學：代謝譜分析和模式識別
  • 多體學整合：整合資料集並避免不良事件
  • 表觀遺傳學：人工智慧/機器學習在染色質和DNA修飾分析的應用
  • 微生物組學：人工智慧/機器學習在微生物組組成和功能的應用
  • 藥物基因體學/毒理基因體學：人工智慧/機器學習在藥物反應預測的應用
  • 單細胞體學：人工智慧/機器學習在細胞類型特異性分析的應用
  • 體學：人工智慧/機器學習在免疫庫和免疫反應分析的應用

第33章體學CRO服務市場中未被滿足的需求

第34章體學CRO服務市場的機會與挑戰

第35章體學CRO服務市場的技術變革

第36章：你需要具備的競爭技能

第37章體學CRO服務市場的小規模企業

第38章：競爭標竿分析

第39章 競爭格局分析

第40章 重大併購

  • Mapmygenome Acquired Microbiome Insights
  • Momentum Biotechnologies Acquired OmicScouts GmbH
  • Crown Bioscience Acquired Indivumed GmbH

第41章體學CRO服務市場的最新趨勢

第42章 機遇與策略

  • 2029年全球體學CRO服務市場：提供新機會的國家
  • 2029年全球體學CRO服務市場：新興細分市場機會
  • 2029年全球體學CRO服務市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手策略

第43章體學CRO服務市場：結論與建議

  • 結論
  • 建議

第44章附錄

簡介目錄
Product Code: PS5MOCSR01_O25Q4

Omics CRO (Contract Research Organization) services refer to outsourced research solutions specializing in large-scale biological data analysis in fields such as genomics, transcriptomics, proteomics, metabolomics, and epigenomics. These services offer comprehensive support, encompassing sample processing, high-throughput data generation, bioinformatics analysis, and interpretation, to expedite research and development in pharmaceuticals, biotechnology, and personalized medicine. The primary purpose of omics CRO services is to enable organizations to conduct complex, high-volume omics studies efficiently without incurring significant investment in in-house infrastructure.

The omics CRO services market consists of sales, by entities (organizations, sole traders, or partnerships) of outsourced research and analytical services that apply different technologies for drug discovery, precision medicine, and biomarker identification.

The global omics CRO services market reached a value of nearly $34,209.94 million in 2024, having grown at a compound annual growth rate (CAGR) of 13.55% since 2019. The market is expected to grow from $34,209.94 million in 2024 to $61,628.89 million in 2029 at a rate of 12.49%. The market is then expected to grow at a CAGR of 10.77% from 2029 and reach $ 102,794.04 million in 2034.

Favorable Government Initiatives

During the historic period, the favorable government initiatives supported the growth of the omics CRO services market. Favorable government initiatives, such as increased funding for precision medicine, grants for genomics research, and supportive regulatory frameworks, help omics CRO services by enabling expansion of advanced sequencing, biomarker discovery, and multi-omics capabilities. These policies reduce financial and operational barriers for CROs, encouraging innovation and adoption of cutting-edge technologies. Additionally, government-backed programs for clinical trials and data sharing accelerate research collaborations and global service reach. For instance, in September 2023, the National Institutes of Health (NIH), a US-based government agency, established consortium with an initial funding of $50.3 million to advance multi-omics research, focusing on integrating various omics data types to study health and disease in diverse populations. This initiative provides opportunities for CROs specializing in multi-omics services. Therefore, the favorable government initiatives drove the growth of the omics CRO services market.

Strategic Collaborations To Enhance Technology Integration

Key companies operating in the omics CRO services market are adopting a strategic partnership approach to enhance technology integration and expand market reach. A strategic partnership typically refers to a collaborative relationship between two or more organizations where they combine their resources, expertise, and efforts to achieve common goals or objectives. For instance, in November 2024, Frontage Laboratories, US-based contract research organization (CRO) providing integrated preclinical, clinical, and analytical services, partnered with Medicover Integrated Clinical Services (MICS), a Poland-based clinical and diagnostic services provider, his strategic partnership aims to integrate Frontage's clinical trial services with Medicover's advanced genomic testing solutions. Medicover, operating over 100 laboratories across 13 countries, provides comprehensive genomic analysis services, including next-generation sequencing (NGS), molecular pathology, and pharmacogenomics.

The global omics CRO services market is fairly concentrated, with a large player operating in the market. The top ten competitors in the market made up to 15.12% of the total market in 2024.

Omics CRO Services Global Market Opportunities And Strategies To 2034 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global omics CRO services market as it emerges from the COVID-19 shut down.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.

Where is the largest and fastest-growing market for omics CRO services? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The omics CRO services market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider omics CRO services market; and compares it with other markets.

The report covers the following chapters

  • Introduction And Market Characteristics- Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by type of omics services, by technology platform, by application and by end-user.
  • Key Trends- Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
  • Growth Analysis And Strategic Analysis Framework- Analysis on PESTEL, end use industries, market growth rate, global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
  • Market Segmentation- Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by type of omics services, by technology platform, by application and by end-user in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
  • Regional Market Size And Growth- Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
  • Competitive Landscape- Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
  • Competitive Benchmarking- Briefs on the financials comparison between major players in the market.
  • Competitive Dashboard- Briefs on competitive dashboard of major players.
  • Key Mergers And Acquisitions- Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
  • Recent Developments- Information on recent developments in the market covered in the report.
  • Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
  • Conclusions And Recommendations- This section includes recommendations for omics CRO services providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
  • Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Markets Covered:

  • 1) By Type Of Omics Services: Genomics; Transcriptomics; Proteomics; Metabolomics; Lipidomics; Multiomics; Single-Cell Omics; Other Type Of Omics Services
  • 2) By Technology Platform: Next-Generation Sequencing (NGS); Microarray Technology; Mass Spectrometry; Chromatography; Bioinformatics Tools; Other Technology Platforms
  • 3) By Application: Drug Discovery And Development; Diagnostics; Personalized Medicine; Other Applications
  • 4) By End Users: Research And Academic Institutions; Pharmaceutical And Biotechnology Companies; Clinical And Diagnostic Laboratories
  • Companies Mentioned: Labcorp Holding Inc. (including Covance); Thermo Fisher Scientific Inc. (PPD); Charles River Laboratories International Inc.; Eurofins Scientific SE; BGI Genomics Co. Ltd.
  • Countries: China; India; Japan; USA; Canada; UK; Germany; France; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time-series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; omics CRO services indicators comparison.
  • Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Table of Contents

1 Executive Summary

  • 1.1 Omics CRO Services - Market Attractiveness And Macro Economic Landscape

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

  • 6.1 General Market Definition
  • 6.2 Summary
  • 6.3 Omics CRO Services Market Definition And Segmentations
  • 6.4 Market Segmentation By Type Of Omics Services
    • 6.4.1 Genomics
    • 6.4.2 Transcriptomics
    • 6.4.3 Proteomics
    • 6.4.4 Metabolomics
    • 6.4.5 Lipidomics
    • 6.4.6 Multiomics
    • 6.4.7 Single-Cell Omics
    • 6.4.8 Other Type Of Omics Services
  • 6.5 Market Segmentation By Technology Platform
    • 6.5.1 Next-Generation Sequencing (NGS)
    • 6.5.2 Microarray Technology
    • 6.5.3 Mass Spectrometry
    • 6.5.4 Chromatography
    • 6.5.5 Bioinformatics Tools
    • 6.5.6 Other Technology Platforms
  • 6.6 Market Segmentation By Application
    • 6.6.1 Drug Discovery And Development
    • 6.6.2 Diagnostics
    • 6.6.3 Personalized Medicine
    • 6.6.4 Other Applications
  • 6.7 Market Segmentation By End Users
    • 6.7.1 Research And Academic Institutions
    • 6.7.2 Pharmaceutical And Biotechnology Companies
    • 6.7.3 Clinical And Diagnostic Laboratories

7 Major Market Trends

  • 7.1 Strategic Collaborations To Enhance Technology Integration
  • 7.2 Strategic Collaborations Driving Advanced Spatial Transcriptomics
  • 7.3 Next-Generation Organoid-Based Screening Solutions

8 Global Omics CRO Services Growth Analysis And Strategic Analysis Framework

  • 8.1 Global Omics CRO Services PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
    • 8.1.1 Political
    • 8.1.2 Economic
    • 8.1.3 Social
    • 8.1.4 Technological
    • 8.1.5 Environmental
    • 8.1.6 Legal
  • 8.2 Analysis Of End Users (B2B)
    • 8.2.1 Research And Academic Institutions
    • 8.2.2 Pharmaceutical And Biotechnology Companies
    • 8.2.3 Clinical And Diagnostic Laboratories
  • 8.3 Global Omics CRO Services Market Size And Growth Analysis
  • 8.4 Historic Market Growth, 2019 - 2024, Value ($ Million)
    • 8.4.1 Market Drivers 2019 - 2024
    • 8.4.2 Market Restraints 2019 - 2024
  • 8.5 Forecast Market Growth, 2024 - 2029, 2034F Value ($ Million)
  • 8.6 Forecast Growth Contributors/Factors
    • 8.6.1 Quantitative Growth Contributors
    • 8.6.2 Drivers
    • 8.6.3 Restraints
  • 8.7 Total Addressable Market for the Omics CRO Services Market
    • 8.7.1 TAM Comparison Analysis

9 Global Omics CRO Services Market Segmentation

  • 9.1 Global Omics CRO Services Market, Segmentation By Type Of Omics Services, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 9.2 Global Omics CRO Services Market, Segmentation By Technology Platform, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 9.3 Global Omics CRO Services Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 9.4 Global Omics CRO Services Market, Segmentation By End Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 9.5 Global Omics CRO Services Market, Sub-Segmentation Of Drug Discovery And Development, By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

10 China Market

  • 10.1 Market Overview
    • 10.1.1 Country Information
    • 10.1.2 Market Information
    • 10.1.3 Background Information
    • 10.1.4 Government Initiatives
    • 10.1.5 Regulations
    • 10.1.6 Regulatory Bodies
    • 10.1.7 Major Associations
    • 10.1.8 Taxes Levied
    • 10.1.9 Corporate Tax Structure
    • 10.1.10 Investments
    • 10.1.11 Major Companies
  • 10.2 China Omics CRO Services Market, Segmentation By Type Of Omics Services, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 10.3 China Omics CRO Services Market, Segmentation By Technology Platform, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 10.4 China Omics CRO Services Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 10.5 China Omics CRO Services Market, Segmentation By End Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 10.6 China Omics CRO Services Market, Sub-Segmentation Of Drug Discovery And Development, By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 10.7 India Market
  • 10.8 India Omics CRO Services Market, Segmentation By Type Of Omics Services, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 10.9 India Omics CRO Services Market, Segmentation By Technology Platform, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 10.10 India Omics CRO Services Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 10.11 India Omics CRO Services Market, Segmentation By End Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 10.12 India Omics CRO Services Market, Sub-Segmentation Of Drug Discovery And Development, By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

11 Japan Market

  • 11.1 Market Overview
    • 11.1.1 Country Information
    • 11.1.2 Market Information
    • 11.1.3 Background Information
    • 11.1.4 Government Initiatives
    • 11.1.5 Regulations
    • 11.1.6 Regulatory Bodies
    • 11.1.7 Major Associations
    • 11.1.8 Taxes Levied
    • 11.1.9 Corporate Tax Structure
    • 11.1.10 Investments
    • 11.1.11 Major Companies
  • 11.2 Japan Omics CRO Services Market, Segmentation By Type Of Omics Services, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.3 Japan Omics CRO Services Market, Segmentation By Technology Platform, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.4 Japan Omics CRO Services Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.5 Japan Omics CRO Services Market, Segmentation By End Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.6 Japan Omics CRO Services Market, Sub-Segmentation Of Drug Discovery And Development, By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

12 Europe Market

  • 12.1 Market Overview
    • 12.1.1 Region Information
    • 12.1.2 Market Information
    • 12.1.3 Background Information
    • 12.1.4 Government Initiatives
    • 12.1.5 Regulations
    • 12.1.6 Regulatory Bodies
    • 12.1.7 Major Associations
    • 12.1.8 Taxes Levied
    • 12.1.9 Corporate Tax Structure
    • 12.1.10 Investments
    • 12.1.11 Major Companies
  • 12.2 Europe Omics CRO Services Market, Segmentation By Type Of Omics Services, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.3 Europe Omics CRO Services Market, Segmentation By Technology Platform, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.4 Europe Omics CRO Services Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.5 Europe Omics CRO Services Market, Segmentation By End Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.6 Europe Omics CRO Services Market, Sub-Segmentation Of Drug Discovery And Development, By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.7 Europe Omics CRO Services Market: Country Analysis
  • 12.8 UK Market
  • 12.9 UK Omics CRO Services Market, Segmentation By Type Of Omics Services, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.10 UK Omics CRO Services Market, Segmentation By Technology Platform, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.11 UK Omics CRO Services Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.12 UK Omics CRO Services Market, Segmentation By End Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.13 UK Omics CRO Services Market, Sub-Segmentation Of Drug Discovery And Development, By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.14 Germany Market
  • 12.15 Germany Omics CRO Services Market, Segmentation By Type Of Omics Services, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.16 Germany Omics CRO Services Market, Segmentation By Technology Platform, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.17 Germany Omics CRO Services Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.18 Germany Omics CRO Services Market, Segmentation By End Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.19 Germany Omics CRO Services Market, Sub-Segmentation Of Drug Discovery And Development, By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.20 France Market
  • 12.21 France Omics CRO Services Market, Segmentation By Type Of Omics Services, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.22 France Omics CRO Services Market, Segmentation By Technology Platform, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.23 France Omics CRO Services Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.24 France Omics CRO Services Market, Segmentation By End Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.25 France Omics CRO Services Market, Sub-Segmentation Of Drug Discovery And Development, By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.26 Italy Market
  • 12.27 Italy Omics CRO Services Market, Segmentation By Type Of Omics Services, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.28 Italy Omics CRO Services Market, Segmentation By Technology Platform, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.29 Italy Omics CRO Services Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.30 Italy Omics CRO Services Market, Segmentation By End Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.31 Italy Omics CRO Services Market, Sub-Segmentation Of Drug Discovery And Development, By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.32 Spain Market
  • 12.33 Spain Omics CRO Services Market, Segmentation By Type Of Omics Services, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.34 Spain Omics CRO Services Market, Segmentation By Technology Platform, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.35 Spain Omics CRO Services Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.36 Spain Omics CRO Services Market, Segmentation By End Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.37 Spain Omics CRO Services Market, Sub-Segmentation Of Drug Discovery And Development, By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.38 Rest Of Europe Market
  • 12.39 Rest Of Europe Omics CRO Services Market, Segmentation By Type Of Omics Services, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.40 Rest Of Europe Omics CRO Services Market, Segmentation By Technology Platform, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.41 Rest Of Europe Omics CRO Services Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.42 Rest Of Europe Omics CRO Services Market, Segmentation By End Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.43 Rest Of Europe Omics CRO Services Market, Sub-Segmentation Of Drug Discovery And Development, By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

13 USA Market

  • 13.1 Market Overview
    • 13.1.1 Country Information
    • 13.1.2 Market Information
    • 13.1.3 Background Information
    • 13.1.4 Government Initiatives
    • 13.1.5 Regulations
    • 13.1.6 Regulatory Bodies
    • 13.1.7 Major Associations
    • 13.1.8 Taxes Levied
    • 13.1.9 Corporate Tax Structure
    • 13.1.10 Investments
    • 13.1.11 Major Companies
  • 13.2 USA Omics CRO Services Market, Segmentation By Type Of Omics Services, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.3 USA Omics CRO Services Market, Segmentation By Technology Platform, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.4 USA Omics CRO Services Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.5 USA Omics CRO Services Market, Segmentation By End Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.6 USA Omics CRO Services Market, Sub-Segmentation Of Drug Discovery And Development, By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

14 Canada Market

  • 14.1 Market Overview
    • 14.1.1 Country Information
    • 14.1.2 Market Information
    • 14.1.3 Background Information
    • 14.1.4 Government Initiatives
    • 14.1.5 Regulations
    • 14.1.6 Regulatory Bodies
    • 14.1.7 Major Associations
    • 14.1.8 Taxes Levied
    • 14.1.9 Corporate Tax Structure
    • 14.1.10 Investments
    • 14.1.11 Major Companies
  • 14.2 Canada Omics CRO Services Market, Segmentation By Type Of Omics Services, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.3 Canada Omics CRO Services Market, Segmentation By Technology Platform, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.4 Canada Omics CRO Services Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.5 Canada Omics CRO Services Market, Segmentation By End Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.6 Canada Omics CRO Services Market, Sub-Segmentation Of Drug Discovery And Development, By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

15 Global Competitive Landscape And Company Profiles

  • 15.1 Company Profiles
  • 15.2 Labcorp Holding Inc. (including Covance)
    • 15.2.1 Company Overview
    • 15.2.2 Products And Services
    • 15.2.3 Financial Overview
  • 15.3 Thermo Fisher Scientific Inc. (PPD)
    • 15.3.1 Company Overview
    • 15.3.2 Products And Services
    • 15.3.3 Business Strategy
    • 15.3.4 Financial Overview
  • 15.4 Charles River Laboratories International Inc.
    • 15.4.1 Company Overview
    • 15.4.2 Products And Services
    • 15.4.3 Financial Overview
  • 15.5 Eurofins Scientific SE
    • 15.5.1 Company Overview
    • 15.5.2 Products And Services
    • 15.5.3 Financial Overview
  • 15.6 BGI Genomics Co. Ltd.
    • 15.6.1 Company Overview
    • 15.6.2 Products And Services
    • 15.6.3 Financial Overview

16 Other Major And Innovative Companies

  • 16.1 Novogene Co. Ltd.
    • 16.1.1 Company Overview
    • 16.1.2 Products And Services
  • 16.2 GENEWIZ from Azenta
    • 16.2.1 Company Overview
    • 16.2.2 Products And Services
  • 16.3 Frontage Laboratories
    • 16.3.1 Company Overview
    • 16.3.2 Products And Services
  • 16.4 Somalogic Inc. (SomaScan(R))
    • 16.4.1 Company Overview
    • 16.4.2 Products And Services
  • 16.5 Metabolon Inc.
    • 16.5.1 Company Overview
    • 16.5.2 Products And Services

17 Information On Strengths And Weaknesses Of Top 10 Global Companies

  • 17.1 Labcorp Holding Inc. (including Covance)
    • 17.1.1 Strengths
    • 17.1.2 Weaknesses
  • 17.2 Thermo Fisher Scientific Inc. (PPD)
    • 17.2.1 Strengths
    • 17.2.2 Weaknesses
  • 17.3 Charles River Laboratories
    • 17.3.1 Strengths
    • 17.3.2 Weaknesses
  • 17.4 Eurofins Scientific SE
    • 17.4.1 Strengths
    • 17.4.2 Weaknesses
  • 17.5 BGI Genomics Co. Ltd.
    • 17.5.1 Strengths
    • 17.5.2 Weaknesses
  • 17.6 Novogene Co. Ltd.
    • 17.6.1 Strengths
    • 17.6.2 Weaknesses
  • 17.7 GENEWIZ from Azenta
    • 17.7.1 Strengths
    • 17.7.2 Weaknesses
  • 17.8 Frontage Laboratories
    • 17.8.1 Strengths
    • 17.8.2 Weaknesses
  • 17.9 Somalogic Inc. (SomaScan(R))
    • 17.9.1 Strengths
    • 17.9.2 Weaknesses
  • 17.10 Metabolon Inc.
    • 17.10.1 Strengths
    • 17.10.2 Weaknesses

18 Information On AI/ML Capabilities Of Top 10 Global Companies

  • 18.1 Labcorp Holding Inc. (Including Covance)
    • 18.1.1 Bioinformatics And Genomics Pipelines (NGS, Expression, Multi-Omics)
    • 18.1.2 Clinical and Real-World Data (RWD) with Predictive Analytics
    • 18.1.3 Digital Pathology And Image-Based AI
    • 18.1.4 Cloud Infrastructure and Generative-AI Clinician Tools
    • 18.1.5 Partnerships And External AI/ML Collaborations
  • 18.2 Thermo Fisher Scientific Inc. (PPD)
    • 18.2.1 Accelerator(TM) Drug Development Platform
    • 18.2.2 AI-Powered Clinical Trial Forecasting
    • 18.2.3 PPD(TM) TrueCast AI Solution
    • 18.2.4 Partnership with OpenAI
    • 18.2.5 Integration of AI in Laboratory Services
  • 18.3 Charles River Laboratories
    • 18.3.1 Logica: AI-Powered Drug Discovery Platform
    • 18.3.2 Collaborations with Aitia and Related Sciences
    • 18.3.3 Integration of Omics and New Approach Methodologies
  • 18.4 Eurofins Scientific SE
    • 18.4.1 Eurofins DiscoveryAI: SAFIRE Platform
    • 18.4.2 Eurofins Viracor Bioinformatics & AI Center of Excellence
    • 18.4.3 Cloud-Based Data Analysis Infrastructure
  • 18.5 BGI Genomics Co. Ltd.
    • 18.5.1 GeneT: AI-Powered Genomic Consultation Platform
    • 18.5.2 iGeneT Pro: Comprehensive Bioinformatics Analysis
    • 18.5.3 133111i Multi-Omics Precision Health Management System
    • 18.5.4 Dr. Tom: Multi-Omics Data Visualization System
    • 18.5.5 Multi-Omics Services for Research and Drug Discovery
  • 18.6 Novogene Co. Ltd.
    • 18.6.1 NovoMagic: Cloud-Based Bioinformatics Platform
    • 18.6.2 Novi: AI-Powered RNA-Seq Analysis Assistant
    • 18.6.3 C2-Intelligence Platform: AI-Powered Cancer Detection
    • 18.6.4 Multi-Omics Services for Research and Drug Discovery
  • 18.7 GENEWIZ from Azenta
    • 18.7.1 Strategic Partnership with Form Bio
    • 18.7.2 Advanced Sequencing Technologies
    • 18.7.3 3. Comprehensive Bioinformatics Solutions
    • 18.7.4 Multi-Omics Services for Research and Drug Discovery
  • 18.8 Frontage Laboratories
    • 18.8.1 Genomics and Omics Services
    • 18.8.2 Drug Discovery and Development Services
    • 18.8.3 Biomarker and Precision Medicine
    • 18.8.4 AI/ML Integration in Omics Services
  • 18.9 Somalogic Inc. (SomaScan(R))
    • 18.9.1 AI/ML Integration in SomaScan(R) Proteomics
    • 18.9.2 Omics CRO Servicesand Capabilities
    • 18.9.3 High-Throughput Proteomics
    • 18.9.4 Biomarker Discovery
    • 18.9.5 Clinical and Translational Research
  • 18.10 Metabolon Inc.
    • 18.10.1 Automate Data Curation
    • 18.10.2 Identify Biochemical Signatures
    • 18.10.3 Anomaly Detection

19 Information On Innovations By Top 10 Global Companies Including Description Of Type Of Innovation

  • 19.1 Labcorp Holding Inc. (Including Covance)
    • 19.1.1 Next-Generation Sequencing (NGS) Panel Advancements
  • 19.2 Thermo Fisher Scientific Inc. (PPD)
    • 19.2.1 Expansion of Bioanalytical Laboratory Services in Europe
    • 19.2.2 R&D Partnership with AstraZeneca BioVentureHub
  • 19.3 Charles River Laboratories
    • 19.3.1 Omics and New Approach Methodologies (NAMs) Integration
    • 19.3.2 Automation in Spatial Biology
  • 19.4 Eurofins Scientific SE
    • 19.4.1 Partnership with Hurdle to Enhance Omics Testing Access
    • 19.4.2 Integration of Omics Technologies with New Approach Methodologies (NAMs)
  • 19.5 BGI Genomics Co. Ltd.
    • 19.5.1 Collaboration with Saudi Arabia's National Unified Procurement Company
  • 19.6 Novogene Co. Ltd.
    • 19.6.1 Launch of Spatial Transcriptomics Service
    • 19.6.2 Establishment of Novogene Korea Limited
    • 19.6.3 Certification as Olink(R) Certified Service Provider
  • 19.7 GENEWIZ from Azenta
    • 19.7.1 Launch of Clinical Long-Read Whole Genome Sequencing Test
    • 19.7.2 Strategic Partnership with Form Bio for AAV Gene Therapy
    • 19.7.3 GENEWIZ Week 2025 Workshops
  • 19.8 Frontage Laboratories
    • 19.8.1 Strategic Collaboration with Medicover Integrated Clinical Services
    • 19.8.2 Participation in the 2025 EMGS Annual Meeting
    • 19.8.3 Expansion of Global Drug Discovery and DMPK Leadership
  • 19.9 Somalogic Inc. (SomaScan(R))
    • 19.9.1 Expansion of SomaScan(R) 11K Platform
    • 19.9.2 Early Access Program with Illumina Sequencers
    • 19.9.3 SomaScan(R) Assay Powers Key Insights into Semaglutide Treatment
    • 19.9.4 Illumina's Acquisition of SomaLogic
  • 19.10 Metabolon Inc.
    • 19.10.1 Launch of Integrated Bioinformatics Platform
    • 19.10.2 Introduction of 4-Week Turnaround Time for Commercial Projects
    • 19.10.3 Launch of Microbiome Research Solution
    • 19.10.4 Expansion of Integrated Bioinformatics Platform

20 Information On Technologies Used Specifically For Proteomics, Metabolomics And Lipidomics Platforms/Projects By Top 10 Global Companies

  • 20.1 Labcorp Holding Inc. (including Covance)
    • 20.1.1 Proteomics Technologies
    • 20.1.2 Metabolomics Technologies
    • 20.1.3 Lipidomics Technologies
  • 20.2 Thermo Fisher Scientific Inc.
    • 20.2.1 Proteomics Technologies
    • 20.2.2 Metabolomics Technologies
    • 20.2.3 Lipidomics Technologies
  • 20.3 Charles River Laboratories
    • 20.3.1 Proteomics Technologies
    • 20.3.2 Metabolomics Technologies
    • 20.3.3 Lipidomics Technologies
  • 20.4 Eurofins Scientific SE
    • 20.4.1 Proteomics Technologies
    • 20.4.2 Metabolomics Technologies
    • 20.4.3 Lipidomics Technologies
  • 20.5 BGI Genomics Co. Ltd.
    • 20.5.1 Proteomics Technologies
    • 20.5.2 Metabolomics Technologies
    • 20.5.3 Lipidomics Technologies
  • 20.6 Novogene Co. Ltd.
    • 20.6.1 Proteomics Technologies
    • 20.6.2 Metabolomics Technologies
    • 20.6.3 Lipidomics Technologies
  • 20.7 GENEWIZ from Azenta
    • 20.7.1 Proteomics Technologies
    • 20.7.2 Metabolomics Technologies:
    • 20.7.3 Lipidomics Technologies:
  • 20.8 Frontage Laboratories
    • 20.8.1 Proteomics Technologies
    • 20.8.2 Metabolomics Technologies
    • 20.8.3 Lipidomics Technologies
  • 20.9 Somalogic Inc. (SomaScan)
    • 20.9.1 Proteomics Technologies
    • 20.9.2 Metabolomics Technologies
    • 20.9.3 Lipidomics Technologies
  • 20.10 Metabolon Inc.
    • 20.10.1 Proteomics Technologies
    • 20.10.2 Metabolomics Technologies
    • 20.10.3 Lipidomics Technologies

21 Information On Overall Capabilities And Technologies Including Coverage, Dynamic Range, Sensitivity And Reproducibility For Top 10 Global Companies

  • 21.1 Labcorp Holding Inc. (including Covance)
    • 21.1.1 Overall Capabilities & Technologies
    • 21.1.2 Coverage
    • 21.1.3 Dynamic Range
    • 21.1.4 Sensitivity
    • 21.1.5 Reproducibility
  • 21.2 Thermo Fisher Scientific Inc. (PPD)
    • 21.2.1 Overall Capabilities & Technologies
    • 21.2.2 Coverage
    • 21.2.3 Dynamic Range
    • 21.2.4 Sensitivity
    • 21.2.5 Reproducibility
  • 21.3 Charles River Laboratories
    • 21.3.1 Overall Capabilities & Technologies
    • 21.3.2 Coverage
    • 21.3.3 Dynamic Range
    • 21.3.4 Sensitivity
    • 21.3.5 Reproducibility
  • 21.4 Eurofins Scientific SE
    • 21.4.1 Overall Capabilities & Technologies
    • 21.4.2 Coverage
    • 21.4.3 Dynamic Range
    • 21.4.4 Sensitivity
    • 21.4.5 Reproducibility
  • 21.5 BGI Genomics Co. Ltd.
    • 21.5.1 Overall Capabilities & Technologies
    • 21.5.2 Coverage
    • 21.5.3 Dynamic Range
    • 21.5.4 Sensitivity
    • 21.5.5 Reproducibility
  • 21.6 Novogene Co. Ltd.
    • 21.6.1 Overall Capabilities & Technologies
    • 21.6.2 Coverage
    • 21.6.3 Dynamic Range
    • 21.6.4 Sensitivity
    • 21.6.5 Reproducibility
  • 21.7 GENEWIZ from Azenta
    • 21.7.1 Overall Capabilities & Technologies
    • 21.7.2 Coverage
    • 21.7.3 Dynamic Range
    • 21.7.4 Sensitivity
    • 21.7.5 Reproducibility
  • 21.8 Frontage Laboratories
    • 21.8.1 Overall Capabilities & Technologies
    • 21.8.2 Coverage
    • 21.8.3 Dynamic Range
    • 21.8.4 Sensitivity
    • 21.8.5 Reproducibility
  • 21.9 Somalogic Inc. (SomaScan)
    • 21.9.1 Overall Capabilities & Technologies
    • 21.9.2 Coverage
    • 21.9.3 Dynamic Range
    • 21.9.4 Sensitivity
    • 21.9.5 Reproducibility
  • 21.10 Metabolon Inc.
    • 21.10.1 Overall Capabilities & Technologies
    • 21.10.2 Coverage
    • 21.10.3 Dynamic Range
    • 21.10.4 Sensitivity
    • 21.10.5 Reproducibility

22 List Of Key Players In The Omics CRO Services Market

  • 22.1 Key Players In The Omics Contract Research Organization (CRO) Services Market

23 Europe Competitive Landscape And Company Profiles

  • 23.1 Company Profiles
  • 23.2 Charles River Laboratories International Inc.
    • 23.2.1 Company Overview
    • 23.2.2 Products And Services
  • 23.3 Labcorp Holdings Inc.
    • 23.3.1 Company Overview
    • 23.3.2 Products And Services
  • 23.4 Thermo Fisher Scientific Inc.
    • 23.4.1 Company Overview
    • 23.4.2 Products And Services
  • 23.5 Eurofins Scientific SE.
    • 23.5.1 Company Overview
    • 23.5.2 Products And Services
  • 23.6 BGI Genomics Co. Ltd.
    • 23.6.1 Company Overview
    • 23.6.2 Products And Services
  • 23.7 Novogene Co. Ltd.
    • 23.7.1 Company Overview
    • 23.7.2 Products And Services
  • 23.8 GENEWIZ from Azenta
    • 23.8.1 Company Overview
    • 23.8.2 Products And Services
  • 23.9 Frontage Laboratories
    • 23.9.1 Company Overview
    • 23.9.2 Products And Services
  • 23.10 Somalogic Inc.
    • 23.10.1 Company Overview
    • 23.10.2 Products And Services
  • 23.11 Metabolon Inc.
    • 23.11.1 Company Overview
    • 23.11.2 Products And Services

24 UK Competitive Landscape And Company Profiles

  • 24.1 Short Profiles
  • 24.2 Eurofins Scientific SE
    • 24.2.1 Company Overview
    • 24.2.2 Products And Services
  • 24.3 Charles River Laboratories Company
    • 24.3.1 Company Overview
    • 24.3.2 Products And Services
  • 24.4 Labcorp Holding Inc.
    • 24.4.1 Company Overview
    • 24.4.2 Products And Services
  • 24.5 Thermo Fisher Scientific Inc.
    • 24.5.1 Company Overview
    • 24.5.2 Products And Services
  • 24.6 BGI Genomics Co. Ltd.
    • 24.6.1 Company Overview
    • 24.6.2 Products And Services
  • 24.7 Novogene Co. Ltd.
    • 24.7.1 Company Overview
    • 24.7.2 Products And Services
  • 24.8 GENEWIZ from Azenta
    • 24.8.1 Company Overview
    • 24.8.2 Products And Services
  • 24.9 Frontage Laboratories
    • 24.9.1 Company Overview
    • 24.9.2 Products And Services
  • 24.10 Metabolon Inc.
    • 24.10.1 Company Overview
    • 24.10.2 Products And Services
  • 24.11 Somalogic Inc.
    • 24.11.1 Company Overview
    • 24.11.2 Products And Services

25 Germany Competitive Landscape And Company Profiles

  • 25.1 Short Profiles
  • 25.2 Labcorp Holding Inc. (including Covance)
    • 25.2.1 Company Overview
    • 25.2.2 Products And Services
  • 25.3 Thermo Fisher Scientific Inc. (PPD)
    • 25.3.1 Company Overview
    • 25.3.2 Products And Services
  • 25.4 Eurofins Scientific SE
    • 25.4.1 Company Overview
    • 25.4.2 Products And Services
  • 25.5 Charles River Laboratories
    • 25.5.1 Company Overview
    • 25.5.2 Products And Services
  • 25.6 BGI Genomics Co. Ltd.
    • 25.6.1 Company Overview
    • 25.6.2 Products And Services
  • 25.7 Novogene Co. Ltd.
    • 25.7.1 Company Overview
    • 25.7.2 Products And Services
  • 25.8 GENEWIZ from Azenta
    • 25.8.1 Company Overview
    • 25.8.2 Products And Services
  • 25.9 Somalogic Inc. (SomaScan(R))
    • 25.9.1 Company Overview
    • 25.9.2 Products And Services
  • 25.10 Centogene GmbH
    • 25.10.1 Company Overview
    • 25.10.2 Products And Services
  • 25.11 Frontage Laboratories
    • 25.11.1 Company Overview
    • 25.11.2 Products And Services

26 USA Competitive Landscape And Company Profiles

  • 26.1 Short Profiles
  • 26.2 Labcorp Holding Inc. (including Covance)
    • 26.2.1 Company Overview
    • 26.2.2 Products And Services
  • 26.3 Thermo Fisher Scientific Inc. (PPD)
    • 26.3.1 Company Overview
    • 26.3.2 Products And Services
  • 26.4 Charles River Laboratories
    • 26.4.1 Company Overview
    • 26.4.2 Products And Services
  • 26.5 Eurofins Scientific SE
    • 26.5.1 Company Overview
    • 26.5.2 Products And Services
  • 26.6 BGI Genomics Co. Ltd.
    • 26.6.1 Company Overview
    • 26.6.2 Products And Services
  • 26.7 Novogene Co. Ltd.
    • 26.7.1 Company Overview
    • 26.7.2 Products And Services
  • 26.8 GENEWIZ from Azenta
    • 26.8.1 Company Overview
    • 26.8.2 Products And Services
  • 26.9 Frontage Laboratories
    • 26.9.1 Company Overview
    • 26.9.2 Products And Services
  • 26.10 Somalogic Inc. (SomaScan(R))
    • 26.10.1 Company Overview
    • 26.10.2 Products And Services
  • 26.11 Metabolon Inc.
    • 26.11.1 Company Overview
    • 26.11.2 Products And Services

27 Japan Competitive Landscape And Company Profiles

  • 27.1 Short Profiles
  • 27.2 Eurofins Scientific SE
    • 27.2.1 Company Overview
    • 27.2.2 Products And Services
  • 27.3 Charles River Laboratories
    • 27.3.1 Company Overview
    • 27.3.2 Products And Services
  • 27.4 Thermo Fisher Scientific Inc. (PPD)
    • 27.4.1 Company Overview
    • 27.4.2 Products And Services
  • 27.5 BGI Genomics Co. Ltd.
    • 27.5.1 Company Overview
    • 27.5.2 Products And Services
  • 27.6 Labcorp Holding Inc. (including Covance)
    • 27.6.1 Company Overview
    • 27.6.2 Products And Services
  • 27.7 Novogene Co. Ltd.
    • 27.7.1 Company Overview
    • 27.7.2 Products And Services
  • 27.8 GENEWIZ from Azenta
    • 27.8.1 Company Overview
    • 27.8.2 Products And Services
  • 27.9 Frontage Laboratories
    • 27.9.1 Company Overview
    • 27.9.2 Products And Services
  • 27.10 Somalogic Inc. (SomaScan(R))
    • 27.10.1 Company Overview
    • 27.10.2 Products And Services
  • 27.11 Centogene GmbH
    • 27.11.1 Company Overview
    • 27.11.2 Products And Services

28 List Of Key Omics CRO Services Companies For The Countries

    • 28.1.1 France
    • 28.1.2 Italy
    • 28.1.3 Spain
    • 28.1.4 Rest Of Europe
    • 28.1.5 Canada
    • 28.1.6 China
    • 28.1.7 India

29 Current Uses Of AI/ML In Technology Platforms In Omics CRO Services Market

  • 29.1 Next-Generation Sequencing (NGS)
  • 29.2 Microarray Technology
  • 29.3 Mass Spectrometry
  • 29.4 Chromatography
  • 29.5 Bioinformatics Tools
  • 29.6 Other Technology Platforms

30 List Of Largest Customer Companies

31 Relative Demand/Size Of Service

  • 31.1 Target Validation
  • 31.2 De-Risking Projects
  • 31.3 Hit-To-Lead
  • 31.4 Biomarker Identification
  • 31.5 Manufacturing Process Improvements
  • 31.6 Drug Substance Analysis
  • 31.7 Toxicology Evaluations
  • 31.8 Visualization Of Data
  • 31.9 AI/ML Interpretations

32 Usage Frequency Of AI/ML In Decision Making Across Omics CRO Projects

  • 32.1 Genomics: Analyze Sequencing Data, And Identify Gene Patterns
  • 32.2 Transcriptomics: Interpret RNA Data, And Quantify Expression
  • 32.3 Proteomics: Classify Proteins, And Detect Modifications
  • 32.4 Metabolomics: Analyze Metabolite Profiles, And Identify Patterns
  • 32.5 Multi-Omics Integration: Integrate Datasets, And Avoid Outcome Incidents
  • 32.6 Epigenomics: AI/ML in Chromatin & DNA Modification Analysis
  • 32.7 Microbiomics: AI/ML in Microbiome Composition and Function
  • 32.8 Pharmacogenomics & Toxicogenomics: AI/ML in Drug Response Prediction
  • 32.9 Single-Cell Omics: AI/ML in Cell-Type Specific Analysis
  • 32.10 Immunomics: AI/ML in Immune Repertoire and Immune Response Profiling

33 Unmet Needs Of The Omics CRO Services Market

  • 33.1 Complexity and High Standards
  • 33.2 Customized, Client-Centric Solutions
  • 33.3 Efficient Data Management and Security
  • 33.4 Faster, Cost-Effective Turnaround
  • 33.5 Comprehensive Coverage Across Drug Development Phases
  • 33.6 Patient Stratification and Recruitment

34 Opportunities And Threats To The Omics CRO Services Market

  • 34.1 Opportunities
    • 34.1.1 Expansion of Precision and Personalized Medicine
    • 34.1.2 Rising Adoption of AI and Data Analytics
    • 34.1.3 Increasing Outsourcing by Biotech and Pharma Firms
    • 34.1.4 Growing Global Demand for Multi-omics Clinical Trials
    • 34.1.5 Investment and Partnerships Across Emerging Markets
  • 34.2 Threats
    • 34.2.1 High Cost and Complexity of Omics Technologies
    • 34.2.2 Data Integration Challenges
    • 34.2.3 Talent scarcity
    • 34.2.4 Ethical And Privacy Concerns
    • 34.2.5 Rising competition

35 Technologies Change In The Omics CRO Services Market

  • 35.1 Mass Spectrometry (MS) Platforms
  • 35.2 Chromatography Systems
  • 35.3 Bioinformatics and Data Analysis Pipelines
  • 35.4 Sample Preparation and Handling Technologies
  • 35.5 Proteomics Quantitation Methods
  • 35.6 Metabolomics and Lipidomics Platforms
  • 35.7 Multi-Omics Integration Tools
  • 35.8 Data Storage and Sharing Technologies

36 Expertise Necessary To Compete In The Omics CRO Services Market

  • 36.1 Core Technical Expertise
  • 36.2 Multi-Omics Data Integration
  • 36.3 End-to-End Service Delivery
  • 36.4 Regulatory and Domain Knowledge
  • 36.5 Emerging Trends and Strategic Positioning

37 Small Players In The Omics CRO Services Market

  • 37.1 North America
    • 37.1.1 Dalton Bioanalytics
    • 37.1.2 Sapient Bioanalytics
    • 37.1.3 MS Bioworks Company
    • 37.1.4 Panome Bio
    • 37.1.5 Allumiqs
  • 37.2 Europe
    • 37.2.1 OmicScouts GmbH
    • 37.2.2 Sciomics GmbH
    • 37.2.3 PreOmics GmbH
    • 37.2.4 Biognosys AG
    • 37.2.5 GenomeScan

38 Competitive Benchmarking

39 Competitive Dashboard

40 Key Mergers And Acquisitions

  • 40.1 Mapmygenome Acquired Microbiome Insights
  • 40.2 Momentum Biotechnologies Acquired OmicScouts GmbH
  • 40.3 Crown Bioscience Acquired Indivumed GmbH

41 Recent Development In Omics CRO Services Market

  • 41.1 Cutting-Edge Facility Supports End-to-End Multi-Omics Research and Product InnovationI

42 Opportunities And Strategies

  • 42.1 Global Omics CRO Services Market In 2029 - Countries Offering Most New Opportunities
  • 42.2 Global Omics CRO Services Market In 2029 - Segments Offering Most New Opportunities
  • 42.3 Global Omics CRO Services Market In 2029 - Growth Strategies
    • 42.3.1 Market Trend Based Strategies
    • 42.3.2 Competitor Strategies

43 Omics CRO Services Market, Conclusions And Recommendations

  • 43.1 Conclusions
  • 43.2 Recommendations
    • 43.2.1 Product
    • 43.2.2 Place
    • 43.2.3 Price
    • 43.2.4 Promotion
    • 43.2.5 People

44 Appendix

  • 44.1 Geographies Covered
  • 44.2 Market Data Sources
  • 44.3 Research Methodology
  • 44.4 Currencies
  • 44.5 The Business Research Company
  • 44.6 Copyright and Disclaimer